Chlorproguanil - Dapsone - Artesunate versus artemether - Lumefantrine: A randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Premji, Zul ^a   Umeh, Rich E ^b   Owusu Agyei, Seth ^c   Esamai, Fabian ^d   Ezedinachi, Emmanuel U ^e   Oguche, Stephen ^f   Borrmann, Steffen ^g,h   Sowunmi, Akintunde ⁱ   Duparc, Stephan ^j   Kirby, Paula L ^k   Pamba, Allan ^k   Kellam, Lynda ^k   Guiguemdé, Robert ^l   Greenwood, Brian ^m   Ward, Stephen A ⁿ   Winstanley, Peter A ^o  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UNIVERSITY OF NIGERIA   (Nigeria)

^c Kintampo Health Research Center   (Ghana)

^d MOI UNIVERSITY   (Kenya)

^e UNIVERSITY OF CALABAR   (Nigeria)

^f UNIVERSITY OF JOS   (Nigeria)

^g KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF IBADAN   (Nigeria)

^j Medicines for Malaria Venture   (Switzerland)

^k GLAXOSMITHKLINE   (United Kingdom)

^l CENTRE MURAZ   (Burkina Faso)

^m LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁿ LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^o UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; BENFLUMETOL; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; CHLORPROGUANIL; DAPSONE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PROGUANIL;

ADOLESCENT; AFRICA; ANEMIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; GAMETOCYTE; GLYCOGEN STORAGE DISEASE TYPE 1; HEMATURIA; HEMOGLOBINURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HETEROZYGOSITY; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALARIA; MALARIA FALCIPARUM; MALE; METHEMOGLOBINEMIA; MORTALITY; MULTIPLE CYCLE TREATMENT; PARASITEMIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; REINFECTION; RETICULOCYTE COUNT; SEPSIS; SICKLE CELL ANEMIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; MULTICENTER STUDY;

ARTESUNATE; PLASMODIUM FALCIPARUM;

ADOLESCENT; AFRICA; ANTIMALARIALS; ARTEMISININS; CHILD; CHLOROGUANIDE; DAPSONE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA, FALCIPARUM; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 68949200963     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006682     Document Type: Article

References (36)

1. World Health Organisation (2005) World Malaria Report. Geneva: World Health Organisation, Available online at: http://rbm.who.int/wmr2005/ (Last accessed 23rd August, 2008).
2. Fegan GW, Noor AM, Akhwale WS, Cousens S, Snow RW (2007) Effect of expanded insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. Lancet 370: 1035-1039.
3. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Tostmann A, et al. (2006) Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 193: 1151-1159.
4. Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, et al. (2005) Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med 2: e92.
5. World Health Organisation (2006) Guidelines for the treatment of malaria. Geneva: World Health Organisation, Available online at: http://malaria.who.int/docs/TreatmentGuidelines2006.pdf (Last accessed 22nd August, 2008).
6. Wootton DG, Opara H, Biagini GA, Kanjala MK, Duparc S, et al. (2008) Open-label comparative clinical study of chlorproguanil-dapsone fixed dose combination (Lapdap) alone or with three different doses of artesunate for uncomplicated Plasmodium falciparum malaria. PLoS ONE 3: e1779.
7. Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, et al. (2004) Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet 363: 1843-1848.
8. Degowin RL, Eppes RB, Powell RD, Carson PE (1966) The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ 35: 165-179.
9. Beutler E, Yeh M, Fairbanks VF (1962) The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker. Proc Natl Acad Sci U S A 48: 9-16.
10. Luzzatto L, Mehta A, Vulliamy T (2001) Glucose-6-phosphate dehydrogenase deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. New York: McGraw Hill, pp 4517-4553.
11. Beutler E, Duparc S (2007) Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 77: 779-789.
12. World Health Organisation (2004) Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparummalaria in Africa: report of a technical consultation convened by WHO. Geneva: World Health Organisation, Available online at: http://www.who.int/malaria/docs/LapDap.pdf (Last accessed 23rd July, 2008).
13. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, et al. (2005) Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99: 459-467.
14. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, et al. (2006) Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg 74: 991-998.
15. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM (2008) High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 13: 635-643.
16. Meremikwu M, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, et al. (2006) Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J 5: 43.
17. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, et al. (2005) Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41: 1079-1086.
18. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, et al. (2005) Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine-artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365: 1474-1480.
19. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, et al. (2007) Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 45: 1453-1461.
20. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, et al. (2007) Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369: 491-498.
21. World Health Organisation (2003) Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50). Geneva: World Health Organisation, Available online at: http://www.who.int/malaria/docs/ProtocolWHO.pdf (Last accessed 6th July, 2008).
22. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G (2003) Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 68: 133-139.
23. Medicines for Malaria Venture, World Health Organisation (2008) Methods and techniques for clinical trials on anti-malarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organisation, Available online at: http://www.who.int/malaria/docs/ drugresistance/MalariaGenotyping.pdf (Last accessed 25th July, 2008).
24. Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT (1989) Molecular heterogeneity of glucose-6-phosphate dehydrogenase A. Blood 74: 2550-2555.
25. Nafa K, Reghis A, Osmani N, Baghli L, Ait-Abbes H, et al. (1994) At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria. Hum Genet 94: 513-517.
26. Poggi V, Town M, Foulkes NS, Luzzatto L (1990) Identification of a single base change in a new human mutant glucose-6-phosphate dehydrogenase gene by polymerase-chain-reaction amplification of the entire coding region from genomic DNA. Biochem J 271: 157-160.
27. Samilchuk E, D'Souza B, Al-Awadi S (1999) Population study of common glucose-6-phosphate dehydrogenase mutations in Kuwait. Hum Hered 49: 41-44.
28. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, et al. (2008) An open label, randomised trial of artesunate+amodiaquine, artesunate-chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS ONE 3: e2530.
29. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ (2000) Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 44: 697-704.
30. Simpson JA, Hughes D, Manyando C, Bojang K, Aarons L, et al. (2006) Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br J Clin Pharmacol 61: 289-300.
31. Ademowo OG, Falusi AG (2002) Molecular epidemiology and activity of erythrocyte G6PD variants in a homogeneous Nigerian population. East Afr Med J 79: 42-44.
32. World Health Organisation (2005) Leprosy (Fact sheet Nu101). Geneva: World Health Organisation, Available online at: http://www.who.int/ mediacentre/factsheets/fs101/en/ (Last accessed 26th June, 2008).
33. Lemnge MM, Msangeni HA, Ronn AM, Salum FM, Jakobsen PH, et al. (1997) Maloprim malaria prophylaxis in children living in a holoendemic village in north-eastern Tanzania. Trans R Soc Trop Med Hyg 91: 68-73.
34. Greenwood BM, Greenwood AM, Smith AW, Menon A, Bradley AK, et al. (1989) A comparative study of Lapudrine (chlorproguanil) and Maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children. Trans R Soc Trop Med Hyg 83: 182-188.
35. Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, et al. (2008) High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS ONE 3: e4031.
36. Fanello CI, Karema C, Ngamije D, Uwimana A, Ndahindwa V, et al. (2008) A randomised trial to assess the efficacy and safety of chlorproguanil/ dapsone + artesunate for the treatment of uncomplicated Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 102: 412-420.